EGFR and non-small cell lung carcinoma: Furthermore, early data suggest the antitumour activity of other fourth-generation EGFR TKIs—such as BBT-176, BLU-945, and TQB3804—in patients with Ex19del/T790M/C797S or L858R/T790M/C797S triple mutant advanced NSCLC [17].